Member Info for daveycaferacer

I wondered what had happened to the dispute with Luye regarding Seroquel and found this in the Results on page 68:-

On May 17, 2019, Luye Pharma Hong Kong Ltd. (“Luye”) issued a notice to the Group purporting to terminate a distribution agreement that granted the Group exclusive commercial rights to Seroquel in the PRC for failure to meet a pre-specified target. The Group disagrees with this assertion and believes that Luye have no basis for termination. As a result, the Group commenced legal proceedings in 2019 in order to seek damages. As at December 31, 2020, the legal proceedings are still in progress.

I agree amones, the market wants and expects an Asian listing. I hope this is forthcoming soon in order to correct the valuation and put it the upward trajectory it should be following.

From today's Investors Chronicle:-

https://www.investorschronicle.co.uk/news/2021/03/05/hutchmed-flags-fourfold-sales-increase-this-year/

The market seems unimpressed, probably because of the ramping cash burn but what else can be expected with such a large late stage pipeline! I like the Company's view that "We have the resources to push everything as hard as we can in the
Next 12 – 24 months and the value we will create during that time will really be material"

The Pipeline has been updated on the Company website this afternoon. There was mention today in the Q&A of an Asian listing and the Company reiterated it is still planning on either HK or Shanghai. Matt you mention the fact it is not a pure Biotech play and I agree, but look at Beigene, Hengrui, Genmab etc and you will see P/S or EV/S approaching 20, or in Beigene's case the P/S is 89.

The Company is undervalued in my opinion.

A great set of results, and I love the initial sales on Sulanda so far this year. Realistically $400m in sales should give an mcap of $8bn based on a conservative P/S of 20 which is a fair metric for a rapidly growing but unprofitable Biotech. I look forward to the call, the Analysts notes and digesting today's announcement in detail.

and the new Company name is excellent, I have nothing against China but dropping it from the Company's name is excellent given it is a global Company

The Company website has just been updated in the last hour with a new fresh format

They (We) have an asset and also £1m in cash which was extracted from Tiziana (Shraeholders), by way of a capital reduction, so there is no need for another to buy into the demerger.

Also regular appearances on RedChip Money with Dave isn't good enough and doesn't constitute Shareholder engagement..... and where is Gabriele and what is he doing?

Yes, the way the Accustem listing has been handled is indeed a joke, and the joke is on us

I do not expect any news on Accustem. The Company and its Broker/Advisor are clearly not capable of acknowledging its corporate commitments. The treatment of Shareholders and the deliberate lack of responses by IR is this regard has been shocking. In the unlikely event I get my Accustem shares allocation I will sell immediately because I have no interest in a Company which has such a disregard for its Shareholders.

Mark Slater clearly recognised “Lots of upside still to come” and “Payoff is now some way down the road but will come”

Matt, I agree that things were already built into the price but I'm just a bit surprised that all the huge things coming along in the next 2 or 3 years are not also being factored in. It just seems the valuation is either over-stretched or is way under what it should be, and nothing in between. I have asked Mark Slater a few times about his view on Chi Med and his latest comments on an Investor call were:-

“Lots of upside still to come”
“Payoff is now some way down the road but will come”
“Not a well understood Company”
“Very supportive, still like it very much, doesn’t naturally fit the Fund like it did but that doesn’t mean it’s not a great Company”
“We believe there is still plenty of growth to come but sold down our holding to focus on other Businesses

Biotech investing is full of disappointments on the clinical and regulatory side but sometimes I get the impressions Tiziana is run as a lifestyle business to some degree, with little regard to Shareholders. On the corporate action side missing the odd deadline is fine, but Investors expect updates if deadlines or targets will be missed. Radio silence is not acceptable for a Main Market Listed Company. If you move to the Main Market stop behaving as if you are still on AIM.

I would suggest that everyone goes onto the Tiziana Life Sciences website and clicks on the Contact page, then sends a polite inquiry. Someone suggested Accutsem is now nothing to do with Tiziana since the demerger - that is partially correct but Tiziana's capital reduction means the Company still has an obligation. If they didn't Companies would be hiving off all sorts of assets without any form of recourse.

currently there has been a capital reduction effective 29th October 2020; an asset with a tangible value has been divested from the Company but the Company has not compensated Shareholders.

"The Demerger is expected to become effective on 30 October 2020 and it is expected that Accustem Admission will occur later in Q4, 2020."

I'm very patient but the Company have either let Shareholders down badly or deliberately deceived them.

I've had a share of a valuable asset that I own taken from me and I'd like it back.

I agree Lauders, and I am hoping for a resurrection of the HK Listing.......

We are now back to September 2017 prices, so that's nearly 4 years of progress and it's as if the market hasn't noticed any of it.

Unfortunately RedChip's paid for Saturday broadcast slots will not be enough. In my view Tiziana should instead be focusing on the specialist Biopharma investment community in the United States and not the day-trader community.